Drug boosts fat tissue's calorie-burning ability in lab

June 16, 2013

SAN FRANCISCO-- A drug that mimics the activity of thyroid hormone significantly increases the amount of energy burned by fat tissue and promotes weight loss, an animal study of metabolism finds. The results were presented Sunday at The Endocrine Society's 95th Annual Meeting in San Francisco.

Humans and other mammals have two kinds of fat, or adipose, tissue, which are referred to by color: white or brown. White adipose tissue, or WAT, has low energy-burning capacity. Because of this, WAT is associated with weight gain and obesity, as well as other conditions related to metabolism, which is the process that turns food into energy. These conditions include high cholesterol and blood pressure as well as resistance to the hormone insulin. Combined with excess weight, especially around the torso, these conditions comprise a group of diseases collectively called metabolic syndrome. This syndrome is known to increase the risk of developing heart disease and diabetes.

In contrast, brown adipose tissue, or BAT, burns energy at a much faster rate, in a process called thermogenesis. Because of this accelerated energy usage, BAT actually helps protect against obesity, rather than contributing to it like WAT does.

With obesity quickly becoming an international epidemic, medical researchers are trying to find ways to increase the body's own fat-burning ability. One approach is to increase the amount of fat that is turned into energy during thermogenesis. New research conducted last year in a genetically engineered animal model showed that the activity of white-fat cells could be altered to behave more like brown-fat cells in terms of their fat-burning capabilities. The changes were small, however, so the potential health benefits of this process, aptly termed "beiging," are unclear.

"BAT has the remarkable ability to dissipate excess energy as heat, thus conferring resistance to obesity," said the study's lead author Jean Lin, BS, a graduate research fellow at the Methodist Hospital Research Institute in Houston, TX. "This study has uncovered a new mechanism by which thyroid hormone signaling regulates thermogenesis and metabolic rate and demonstrates the profound therapeutic potential of white fat beiging,"

Lin and her co-investigators examined the beiging effects of the experimental drug called GC-1. In the body, this drug binds to proteins called thyroid hormone receptors, which play a role in turning food into energy when activated by thyroid hormone.

They found that GC-1 increased the metabolism of obese mice by more than 60 percent. Furthermore, this increase in metabolic rate led to significant weight loss within two weeks.

"By inducing thermogenesis in white fat, the compound GC-1 gives fat cells the remarkable ability to dispose of excess calories by converting them to heat instead of storing them as lipid," Lin said.

The National Institutes of Health funded the study.
-end-
Founded in 1916, The Endocrine Society is the world's oldest, largest and most active organization devoted to research on hormones and the clinical practice of endocrinology. Today, The Endocrine Society's membership consists of over 16,000 scientists, physicians, educators, nurses and students in more than 100 countries. Society members represent all basic, applied and clinical interests in endocrinology. The Endocrine Society is based in Chevy Chase, Maryland. To learn more about the Society and the field of endocrinology, visit our site at http://www.endocrine.org. Follow us on Twitter.

The Endocrine Society

Related Obesity Articles from Brightsurf:

11 years of data add to the evidence for using testosterone therapy to treat obesity, including as an alternative to obesity surgery
New research covering 11 years of data presented at this year's European and International Congress on Obesity (ECOICO 2020) show that, in obese men suffering from hypogonadism (low testosterone), treatment with testosterone injections lowers their weight and improves a wide range of other metabolic parameters.

Overlap between immunology of COVID-19 and obesity could explain the increased risk of death in people living with obesity, and also older patients
Data presented in a special COVID-19 session at the European and International Congress on Obesity (ECOICO 2020) suggests that there are overlaps between the immunological disturbances found in both COVID-19 disease and patients with obesity, which could explain the increased disease severity and mortality risk faced by obese patients, and also elderly patients, who are infected by the SARS-CoV-2 virus that causes COVID-19 disease.

New obesity guideline: Address root causes as foundation of obesity management
besity management should focus on outcomes that patients consider to be important, not weight loss alone, and include a holistic approach that addresses the root causes of obesity, according to a new clinical practice guideline published in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/lookup/doi/10.1503/cmaj.191707.

Changing the debate around obesity
The UK's National Health Service (NHS) needs to do more to address the ingrained stigma and discrimination faced by people with obesity, says a leading health psychologist.

Study links longer exposure to obesity and earlier development of obesity to increased risk of type 2 diabetes
Cumulative exposure to obesity could be at least as important as actually being obese in terms of risk of developing type 2 diabetes (T2D), concludes new research published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]).

How much do obesity and addictions overlap?
A large analysis of personality studies has found that people with obesity behave somewhat like people with addictions to alcohol or drugs.

Should obesity be recognized as a disease?
With obesity now affecting almost a third (29%) of the population in England, and expected to rise to 35% by 2030, should we now recognize it as a disease?

Is obesity associated with risk of pediatric MS?
A single-center study of 453 children in Germany with multiple sclerosis (MS) investigated the association of obesity with pediatric MS risk and with the response of first-line therapy in children with MS.

Women with obesity prior to conception are more likely to have children with obesity
A systematic review and meta-analysis identified significantly increased odds of child obesity when mothers have obesity before conception, according to a study published June 11, 2019 in the open-access journal PLOS Medicine by Nicola Heslehurst of Newcastle University in the UK, and colleagues.

Obesity medicine association announces major updates to its adult obesity algorithm
The Obesity Medicine Association (OMA) announced the immediate availability of the 2019 OMA Adult Obesity Algorithm, with new information for clinicians including the relationship between Obesity and Cardiovascular Disease, Diabetes Mellitus, Dyslipidemia, and Cancer; information on investigational Anti-Obesity Pharmacotherapy; treatments for Lipodystrophy; and Pharmacokinetics and Obesity.

Read More: Obesity News and Obesity Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.